We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
Cap. Flow
+$192M
Cap. Flow %
7.6%
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.4M
2
ABBV icon
AbbVie
ABBV
+$31.2M
3
AGN
Allergan plc
AGN
+$24M
4
BAX icon
Baxter International
BAX
+$22.3M
5
GILD icon
Gilead Sciences
GILD
+$20.2M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$59.8M
2
AGN
Allergan Inc
AGN
+$48.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.5M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$22.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.13%
2 Real Estate 3.95%
3 Financials 1.4%
4 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
76
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$5.4M 0.21%
+547,300
New +$6.83M
ACHN
77
DELISTED
Achillion Pharmaceuticals
ACHN
$5.4M 0.21%
+547,300
New +$6.83M
AEGR
78
DELISTED
Aegerion Pharmaceuticals
AEGR
$5.39M 0.21%
+206,000
New +$5.24M
MNTA
79
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.37M 0.21%
353,575
-714,000
-67% -$9.28M
BIIB icon
80
CALL
Biogen
BIIB
$30.7B
$5.15M 0.2%
+12,200
New +$4.81M
INCY icon
81
CALL
Incyte
INCY
$24.9B
$5.13M 0.2%
+56,000
New +$4.63M
ACT.PRA
82
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
$5.06M 0.2%
+5,000
New +$5.23M
DCOY
83
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
CRDF icon
84
Cardiff Oncology
CRDF
$66.2M
$4.43M 0.18%
+9,028
New +$3.85M
WMGI
85
DELISTED
Wright Medical Group Inc
WMGI
$4.03M 0.16%
156,100
– –
ZGNX
86
DELISTED
Zogenix, Inc.
ZGNX
$3.91M 0.15%
+356,351
New +$4.03M
IPCI
87
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$3.89M 0.15%
139,400
-1,000
-0.7% -$24.3K
EPZM
88
DELISTED
Epizyme, Inc
EPZM
$3.76M 0.15%
+200,000
New +$4.13M
ITCI
89
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.58M 0.14%
+150,000
New +$3.36M
AXDX
90
DELISTED
Accelerate Diagnostics
AXDX
$3.25M 0.13%
+14,463
New +$3.02M
SRPT icon
91
Sarepta Therapeutics
SRPT
$1.64B
$3.06M 0.12%
230,300
-115,100
-33% -$1.53M
THC icon
92
Tenet Healthcare
THC
$21.8B
$2.95M 0.12%
+59,500
New +$2.78M
KYTH
93
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$2.79M 0.11%
55,717
-55,716
-50% -$2.34M
ATHN
94
CALL
DELISTED
Athenahealth, Inc.
ATHN
$2.76M 0.11%
+23,100
New +$3.08M
ATHN
95
DELISTED
Athenahealth, Inc.
ATHN
$2.76M 0.11%
+23,100
New +$3.08M
KITE
96
CALL
DELISTED
Kite Pharma, Inc.
KITE
$2.68M 0.11%
+46,500
New +$3.12M
KITE
97
DELISTED
Kite Pharma, Inc.
KITE
$2.68M 0.11%
+46,500
New +$3.12M
MYGN icon
98
CALL
Myriad Genetics
MYGN
$507M
$2.65M 0.1%
+74,800
New +$2.68M
MYGN icon
99
Myriad Genetics
MYGN
$507M
$2.65M 0.1%
74,800
-37,400
-33% -$1.34M
BDSI
100
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.63M 0.1%
250,000
-33,411
-12% -$456K
1 2 3
4
5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Tekla Capital Management deployed $192M of net new capital in Q1 2015, opening 32 new positions and adding to 30 existing holdings. Its largest new stake was Baxter International: 588,384 shares worth $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $28.5M trimmed.

  • Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
  • Tekla Capital Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $33.4M increase.
  • Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
  • Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
  • Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
  • Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
  • Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.

Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.